Skip to main content
Bioceltix S.A. logo

Bioceltix S.A. — Investor Relations & Filings

Ticker · BCX ISIN · PLBCLTX00019 LEI · 259400QZD5JYK8SLZU51 WAR Manufacturing
Open in API
Filings indexed 270 across all filing types
Latest filing 2023-06-27 AGM Information
Country PL Poland
Listing WAR BCX

About Bioceltix S.A.

https://bioceltix.com/en/

Bioceltix S.A. is a biopharmaceutical company that develops stem cell-based medicinal products for veterinary use. The company focuses on creating therapies that utilize Mesenchymal Stem Cells (MSCs) as the active pharmaceutical ingredient. Its product pipeline is aimed at treating immunological and inflammatory conditions in companion animals, including dogs, cats, and horses. A key area of development includes treatments for conditions such as atopic dermatitis in dogs and degenerative joint disease.

Recent filings

Filing Released Lang Actions
Wykaz akcjonariuszy posiadających co najmniej 5 % głosów na Zwyczajnym Walnym Zgromadzeniu w dniu 27 czerwca 2023 r. - Content (PL)
AGM Information Classification · 1% confidence The document text is in Polish and details the list of shareholders who held at least 5% of the votes at the Extraordinary General Meeting ("ZWZ") held on June 27, 2023. It explicitly lists the number of votes and the percentage share for each major shareholder during that specific meeting. This content directly relates to the official results of a shareholder vote at a general meeting. Therefore, the appropriate classification is Declaration of Voting Results & Voting Rights Announcements (DVA). The document is short and contains the results directly, not an announcement about the results.
2023-06-27 Polish
Zmiany w składzie Rady Nadzorczej Emitenta - Content (PL)
Board/Management Information Classification · 1% confidence The document text is a formal announcement in Polish by the Management Board ('Zarząd') of Bioceltix S.A. It explicitly details the resolutions passed during the Ordinary General Meeting ('Zwyczajne Walne Zgromadzenie' or 'ZWZ') held on June 27, 2023. The core content revolves around the dismissal and subsequent appointment of members to the Supervisory Board ('Rada Nadzorcza'), followed by detailed biographies of the newly appointed members. This content directly relates to changes in the company's governance structure and board composition. This aligns perfectly with the definition of 'Board/Management Information' (MANG), which covers announcements of changes in the company's board of directors. Although it mentions the AGM ('ZWZ'), the focus is on the outcome regarding board composition, not general AGM materials or voting results.
2023-06-27 Polish
Treść uchwał podjętych na ZWZA w dniu 27 czerwca 2023 r.
AGM Information Classification · 1% confidence The document text consists entirely of numbered resolutions ("Uchwała nr...") passed by the "Zwyczajne Walne Zgromadzenie" (Ordinary General Meeting) of Bioceltix S.A. on June 27, 2023. These resolutions cover procedural matters (electing a chairman), approving the agenda, approving annual reports (management, financial, supervisory board), covering losses, granting discharge/absolution ('absolutorium') to board members for the 2022 fiscal year, and voting on remuneration. The core content is the formal record of decisions made during an Annual General Meeting (AGM). This directly corresponds to the definition of AGM Information (AGM-R).
2023-06-27 Polish
Treść uchwał podjętych podczas obrad Zwyczajnego Walnego Zgromadzenia w dniu 27 czerwca 2023 r. - Content (PL)
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document text is very short (496 characters) and explicitly states that the management ('Zarząd') is attaching the content of the resolutions ('treść uchwał podjętych') and voting results ('wynikami głosowania') from the Annual General Meeting ('Zwyczajne Walne Zgromadzenie' - ZWZ) held on June 27, 2023. This structure—a brief announcement transmitting the actual results of a shareholder vote—fits the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). It is not the AGM presentation itself (AGM-R), nor is it a general announcement about publishing a report (RPA), as it specifically details the outcome of the vote.
2023-06-27 Polish
Uzyskanie zgody na przeprowadzenie badania na pacjentach klinicznych dla kandydata na produkt leczniczy BCX-EM w Holandii - Content (PL)
Regulatory Filings Classification · 1% confidence The document is a short announcement (1008 characters) from the Management Board ('Zarząd') of Bioceltix S.A. informing the public about receiving a permit from the Dutch Ministry of Agriculture, Nature and Food Quality to conduct a planned field veterinary clinical trial for their product BCX-EM. This concerns a specific regulatory step in product development. Since it is a specific announcement about regulatory approval for a clinical trial, it does not fit perfectly into the main financial report categories (10-K, IR, ER). It is not a Director's Dealing (DIRS), Dividend (DIV), or Capital Change (CAP). Given the nature of the announcement—a specific regulatory milestone related to product development—and its brevity, it is best classified as a general Regulatory Filing (RNS) as it is a mandatory disclosure of a significant event that doesn't fit the other specific categories like M&A (TAR) or Management Changes (MANG). It is a regulatory update, but not a formal financial report or a specific legal proceeding report (LTR). RNS serves as the best general regulatory disclosure fallback.
2023-06-22 Polish
Raport niezależnego biegłego rewidenta z wykonania usługi w zakresie oceny sprawozdania o wynagrodzeniach Bioceltix S.A. sporządzonego za 2022 rok
Audit Report / Information Classification · 1% confidence The document is explicitly titled "Raport niezależnego biegłego rewidenta z wykonania usługi w zakresie oceny sprawozdania o wynagrodzeniach" (Report of the independent auditor on the performance of the service regarding the assessment of the remuneration report). It details the scope of work performed by an independent auditor (biegły rewident) to provide rational assurance on the completeness of the remuneration report ('sprawozdanie o wynagrodzeniach') for BIOCELTIX S.A. for the year 2022, referencing specific Polish public offering laws (art. 90g). This document is the auditor's opinion/report on the remuneration statement, not the remuneration statement itself, nor a general annual report (10-K). The closest matching category is 'Audit Report / Information' (AR), as it is a standalone report from an auditor regarding specific financial/governance information, distinct from a full annual report or an earnings release. FY 2022
2023-06-20 Polish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.